SUPPLEMENTAL REFERENCES


74. Socinski MA, Rittmeyer A, Shapovalov D, Orlandi F, McCleod M, Soo RA, et al. IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC. Ann Oncol 2018;29 Supplement 8:viii750-1.


77. West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. Atezolizumab in combination with carbo-


Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable...


